A Phase II Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma | MicrobiomeTrials← Back to trialsNCT07637578
A Phase II Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-08Est. Completion: 2029-10
Enrollment target: 46 participants Other microbiome trials you might be interested in
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
Background:
Multiple myeloma (MM) is a type of blood cancer that affects a person s immunity. MM returns after treatmen…
Bethesda, United StatesCompleted Jan 1, 2033
Multiple Myeloma (MM)
This is a single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary effic…
Nanjing, ChinaEst. completion Dec 31, 2027